Nanotherapeutic systems for local treatment of brain tumors.

Wiley Interdiscip Rev Nanomed Nanobiotechnol

Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.

Published: January 2018

Malignant brain tumor, including the most common type glioblastoma, are histologically heterogeneous and invasive tumors known as the most devastating neoplasms with high morbidity and mortality. Despite multimodal treatment including surgery, radiotherapy, chemotherapy, and immunotherapy, the disease inevitably recurs and is fatal. This lack of curative options has motivated researchers to explore new treatment strategies and to develop new drug delivery systems (DDSs); however, the unique anatomical, physiological, and pathological features of brain tumors greatly limit the effectiveness of conventional chemotherapy. In this context, we review the recent progress in the development of nanoparticle-based DDSs aiming to address the key challenges in transporting sufficient amount of therapeutic agents into the brain tumor areas while minimizing the potential side effects. We first provide an overview of the standard treatments currently used in the clinic for the management of brain cancers, discussing the effectiveness and limitations of each therapy. We then provide an in-depth review of nanotherapeutic systems that are intended to bypass the blood-brain barrier, overcome multidrug resistance, infiltrate larger tumorous tissue areas, and/or release therapeutic agents in a controlled manner. WIREs Nanomed Nanobiotechnol 2018, 10:e1479. doi: 10.1002/wnan.1479 This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701865PMC
http://dx.doi.org/10.1002/wnan.1479DOI Listing

Publication Analysis

Top Keywords

nanotherapeutic systems
8
brain tumors
8
brain tumor
8
therapeutic agents
8
brain
5
systems local
4
local treatment
4
treatment brain
4
tumors malignant
4
malignant brain
4

Similar Publications

RNA nanotherapeutics for hepatocellular carcinoma treatment.

Theranostics

January 2025

Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness of current therapeutic options for advanced-stage disease. The efficacy of traditional treatments is often compromised by the intricate liver microenvironment and the inherent heterogeneity. RNA-based therapeutics offer a promising alternative, utilizing the innovative approach of targeting aberrant molecular pathways and modulating the tumor microenvironment.

View Article and Find Full Text PDF

Nanocarriers for Delivery of Anticancer Drugs: Current Developments, Challenges, and Perspectives.

Pharmaceutics

November 2024

Department of Cell Biology and Molecular Genetics, Sri Devraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar 563103, India.

Cancer, the most common condition worldwide, ranks second in terms of the number of human deaths, surpassing cardiovascular diseases. Uncontrolled cell multiplication and resistance to cell death are the traditional features of cancer. The myriad of treatment options include surgery, chemotherapy, radiotherapy, and immunotherapy to treat this disease.

View Article and Find Full Text PDF

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system characterized by demyelination, neuroinflammation, and neurodegeneration. Recent studies highlight the role of cerebral iron (Fe) accumulation in exacerbating MS pathophysiology. Fe, essential for neural function, contributes to oxidative stress and inflammation when dysregulated, particularly in the brain's gray matter and demyelinated lesions.

View Article and Find Full Text PDF

Progressing nanotechnology to improve diagnosis and targeted therapy of Diabetic Retinopathy.

Biomed Pharmacother

January 2025

Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.

The inherent limitations of traditional treatments for Diabetic Retinopathy (DR) have spurred the development of various nanotechnologies, offering a safer and more efficient approach to managing the disease. Nanomedicine platforms present promising advancements in the diagnosis and treatment of DR by enhancing imaging capabilities, enabling targeted and controlled drug delivery. These innovations ultimately lead to more effective and personalized treatments with fewer side effects.

View Article and Find Full Text PDF

Injectable, self-healing and phase change nanocomposite gels loaded with two nanotherapeutic agents for mild-temperature, precise and synergistic photothermal-thermodynamic tumor therapy.

J Colloid Interface Sci

December 2024

School of Materials Science and Engineering, Key Laboratory of Advanced Civil Materials of Ministry of Education, Tongji University, Shanghai 201804, PR China. Electronic address:

Hyperthermia has emerged as a popular treatment option due to its high efficacy and seamless integration with other therapeutic approaches. To enhance treatment outcomes, hydrogels loaded with photothermal agents and activated by near-infrared (NIR) light for localized tumor therapy have attracted considerable attention. This approach minimizes drug dosage and mitigates the adverse effects of systemic drug delivery on healthy tissues.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!